article thumbnail

Small Molecule of the Year – 2022

Drug Hunter

We asked the global drug discovery community to nominate and vote on their favorite molecule from 2022, and the results are in. The 2022 winner, with the most overall votes across the ten finalist molecules , is BMS’ oral, deuterated allosteric TYK2 inhibitor, deucravacitinib, the first new treatment for plaque psoriasis in nearly a decade.

article thumbnail

Pfizer launches Phase III trial for Lyme disease vaccine  

Drug Discovery World

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. April 2022. 2: Valneva.

Vaccine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medicinal cannabis: Why more clinical trials and better access is needed

Drug Discovery World

It is estimated that there will be 340,000 medicinal cannabis users in Europe in 2022 alone, and the overall market is estiated to grow over 500% over the next three years – with the market value in Germany alone poised to hit over €7 billion by 2027 1. This data is proving useful in testing hypotheses before starting any clinical trials.

article thumbnail

Buoyant UK biotech sector secures £1.8bn investment in 2023

Drug Discovery World

This follows another BIA report in January 2024, which showed that the UK is a global leader in cell and gene therapy (CGT), with significant investment and the highest number of clinical trials in Europe. billion in equity financings, down only 9% from 2022. The key findings of the new report: UK biotechs secured £1.8

Licensing 130
article thumbnail

Accelerated development for Covid-19 monoclonal antibody

Drug Discovery World

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .

article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

The study forecast growth to 2022 and presented an in-depth strategic assessment of the antibody-drug conjugates, highlighting a number of influencing factors impacting or reinforcing market environment, including government policy, technological changes, and market drivers 4.

Marketing 245
article thumbnail

Which diseases are poised to benefit from therapeutic antibody development

Drug Discovery World

billion by 2031, growing at a CAGR of 7% from 2022 to 2031 2 , but is also reflected in data by The Antibody Society, which shows that of the over 100 approved mAbs, around 40% are for cancer 3. billion in 2022 to $53.81 This is not only made clear by the fact that the global cancer mAbs market size was valued at $55.6

Disease 147